Lee Tom Y

disclosed that they own 37.1% of PURE Bioscience (OTCMKTS:PURE) in a Schedule 13D disclosure that was filed with the Securities and Exchange Commission on Friday, December 29th. The investor owns 26,180,154 shares of the stock valued at approximately $24,740,246. The reporting parties listed on the disclosure included Plum Investments, LP, Tom Y Lee and Chang Hwalee. The disclosure is available through the SEC website at this hyperlink.

Shares of PURE Bioscience (OTCMKTS:PURE) remained flat at $$0.95 during trading hours on Friday. The company had a trading volume of 131,326 shares, compared to its average volume of 36,784. PURE Bioscience has a fifty-two week low of $0.83 and a fifty-two week high of $1.36. The company has a market cap of $64.53, a price-to-earnings ratio of -8.59 and a beta of -1.45.

PURE Bioscience (OTCMKTS:PURE) last issued its quarterly earnings results on Thursday, December 14th. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.02). PURE Bioscience had a negative return on equity of 210.88% and a negative net margin of 388.83%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.65 million. analysts expect that PURE Bioscience will post -0.08 EPS for the current fiscal year.

Separately, ValuEngine upgraded shares of PURE Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/pure-bioscience-pure-stake-owned-by-lee-tom-y/1787793.html.

About PURE Bioscience

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Want to see what other hedge funds are holding PURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PURE Bioscience (OTCMKTS:PURE).

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with Analyst Ratings Network's FREE daily email newsletter.